TY - JOUR
T1 - Regulatory considerations for the clinical and research use of transcranial direct current stimulation (tDCS)
T2 - Review and recommendations from an expert panel
AU - Fregni, F.
AU - Nitsche, M. A.
AU - Loo, C. K.
AU - Brunoni, A. R.
AU - Marangolo, P.
AU - Leite, J.
AU - Carvalho, S.
AU - Bolognini, N.
AU - Caumo, W.
AU - Paik, N. J.
AU - Simis, M.
AU - Ueda, K.
AU - Ekhtiari, H.
AU - Luu, P.
AU - Tucker, D. M.
AU - Tyler, W. J.
AU - Brunelin, J.
AU - Datta, A.
AU - Juan, C. H.
AU - Venkatasubramanian, G.
AU - Boggio, P. S.
AU - Bikson, M.
N1 - Funding Information:
F. Fregni is supported by a grant from National Institutes of Health (NIH) (Grant number 1R44NS08063201). A. R. Brunoni is supported by the following grants: 2013 NARSAD Young Investigator from the Brain & Behavior Research Foundation (Grant Number 20493), 2013 FAPESP Young Researcher from the São Paulo State Foundation (Grant Number 20911-5), and National Council for Scientific and Technological Development (CNPq, Grant Number 470904). J. Brunelin is supported by the 2013 NARSAD Young Investigator from the Brain & Behavior Research Foundation (Grant Number 20988). H. Ekhtiari is supported by grants from Tehran University of Medical Sciences. J. Leite (SFRH/ BPD/86027/2012) and S. Carvalho (SFRH/BPD/86041/2012) are supported by grants from the Portuguese Foundation for Science and Technology (FCT). C. H. Juan is supported by MOST (101-2811-H-008-014). G. Venkatasubramanian is supported by the Department of Science and Technology (Government of India) Research Grant (SR/CSI/158/2012) as well as Wellcome Trust/DBT India Alliance Senior Fellowship Research Award (500236/Z/11/Z). N. Bolognini is supported by a F.A.R. grant from the University of Milano-Bicocca. M. Bikson is supported by NIH (NINDS, NIMH, NCI), Wallace H. Coulter Foundation, Grove Foundation, DoD. W. Caumo is supported by National Council for Scientific and Technological Development-CNPq WC-301256/2013-6. The group is also grateful for the support from the Conselho Brasileiro de Neuromodulacao Clinica– Instituto Scala. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2014 Informa Healthcare USA, Inc. All rights reserved.
PY - 2015/3/1
Y1 - 2015/3/1
N2 - The field of transcranial electrical stimulation (tES) has experienced significant growth in the past 15 years. One of the tES techniques leading this increased interest is transcranial direct current stimulation (tDCS). Significant research efforts have been devoted to determining the clinical potential of tDCS in humans. Despite the promising results obtained with tDCS in basic and clinical neuroscience, further progress has been impeded by a lack of clarity on international regulatory pathways. Therefore, a group of research and clinician experts on tDCS were convened to review the research and clinical use of tDCS. This report reviews the regulatory status of tDCS and summarizes the results according to research, off-label, and compassionate use of tDCS in the following countries: Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, South Korea, Taiwan, and the US. Research use, off label treatment, and compassionate use of tDCS are employed in most of the countries reviewed in this study. It is critical that a global or local effort is organized to pursue definite evidence to either approve and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized controlled treatment trials.
AB - The field of transcranial electrical stimulation (tES) has experienced significant growth in the past 15 years. One of the tES techniques leading this increased interest is transcranial direct current stimulation (tDCS). Significant research efforts have been devoted to determining the clinical potential of tDCS in humans. Despite the promising results obtained with tDCS in basic and clinical neuroscience, further progress has been impeded by a lack of clarity on international regulatory pathways. Therefore, a group of research and clinician experts on tDCS were convened to review the research and clinical use of tDCS. This report reviews the regulatory status of tDCS and summarizes the results according to research, off-label, and compassionate use of tDCS in the following countries: Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, South Korea, Taiwan, and the US. Research use, off label treatment, and compassionate use of tDCS are employed in most of the countries reviewed in this study. It is critical that a global or local effort is organized to pursue definite evidence to either approve and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized controlled treatment trials.
KW - Regulatory
KW - Safety
KW - TDCS
UR - http://www.scopus.com/inward/record.url?scp=84928232165&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928232165&partnerID=8YFLogxK
U2 - 10.3109/10601333.2015.980944
DO - 10.3109/10601333.2015.980944
M3 - Review article
AN - SCOPUS:84928232165
SN - 1060-1333
VL - 32
SP - 22
EP - 35
JO - Clinical Research and Regulatory Affairs
JF - Clinical Research and Regulatory Affairs
IS - 1
ER -